Trust Stamp announces allowance by the United States Patent and Trademark Office (“USPTO”) of a Non-Provisional Patent Application in respect of technology designed to identify deep fake and other Generative AI fuelled attacks in identity authentication processes 
Global Media First Drive of G700: A Comprehensive Validation of GAIA Hybrid Off-Road Architecture 
Scandium International Mining Announces Exercise of Options by Chief Executive Officer and Chief Financial Officer Annual Report 2020 Active Biotech AB (publ)
Active Biotech’s Annual Report 2020 is now available for download at www.activebiotech.com. The Annual Report will…
Active Biotech AB Interim report January – March 2021 Â
Financing completed and good progress in the projects First quarter in brief Agreement signed for…
Saniona announces outcome of TO3 warrant exercise
PRESS RELEASE April 22, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on…
U.S. Patents for Nicox’s Latanoprostene Bunod, Commercialized as VYZULTA®, Eligible for Patent Term Extension
Press Release U.S. Patents for Nicox’s Latanoprostene Bunod, Commercialized as VYZULTA®, Eligible for Patent Term…
ObsEva Annual General Meeting 2021
Geneva, Switzerland and Boston, MA – April 22, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and…
Roche purchases shares in tender offer for GenMark Diagnostics, Inc.
Basel, 22 April 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) and GenMark Diagnostics, Inc….
Idorsia announces financial results for the first quarter 2021 – substantial progress made across the pipeline – launch preparations well underway
Allschwil, Switzerland – April 22, 2021 Idorsia Ltd (SIX: IDIA) today announced its financial results…
New long-term share-based incentive program
Orphazyme A/SCompany announcement        No. 13/2021Company Registration No. 32266355 Copenhagen, Denmark, April 22, 2021 – Orphazyme A/S…
Zymergen Announces Pricing of Upsized Initial Public Offering
EMERYVILLE, Calif., April 21, 2021 (GLOBE NEWSWIRE) — Zymergen Inc. (“Zymergen”), one of the world’s…
Saniona Updates Tesomet Clinical Development Timelines Based on Manufacturing Feedback from U.S. FDA
PRESS RELEASE April 22, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on…
ALX Oncology to Present ALX148 Clinical Data at the ESMO 23rd World Congress on Gastrointestinal Cancer
Updated results will be presented from ASPEN-01, the ongoing Phase 1b Study of ALX148Â in combination…
Ascendis Pharma A/S Announces Presentations for TransCon™ hGH at Upcoming Medical Conferences
COPENHAGEN, Denmark, April 21, 2021 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical…
PRA Health Sciences expands its response to COVID-19 with pharmacovigilance solutions for authorized vaccines and therapeutics
PRA offers post-authorization safety solutions to keep up with the speed of COVID-19 vaccine and…
Freeline to Participate in Upcoming Investor Conferences in April and May 2021
LONDON, April 21, 2021 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company”…
Senti Bio to Present Data from CAR-NK Cell Oncology Pipeline at Upcoming Scientific Conferences
ASGCT and ISCT abstracts highlight the Company’s progress with gene circuit-engineered allogeneic CAR-NK cell therapy…
MDxHealth announces listing of 9,639,489 existing shares on Euronext Brussels following the January 2021 Capital Increase
NEWS RELEASE – REGULATED INFORMATION 21 April 2021, 10:00 p.m. CET IRVINE, CA, and HERSTAL, BELGIUM –…
Basilea shareholders approve all proposals of the board of directors at the annual general meeting
Basel, Switzerland, April 21, 2021 Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that shareholders approved…
Valneva Initiates Phase 3 Clinical Trial for its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001
Saint-Herblain (France), April 21, 2021 – Valneva SE, a specialty vaccine company focused on the…
Onxeo Reports Full-Year 2020 Financial Results and Provides Business Update
Several major clinical milestones achieved in 2020 by AsiDNA™, including promising initial results in combination…
22nd Century Group Issues Annual Letter to Shareholders
Company’s Confidence in MRTP Authorization is High; Launch of VLN® is Only the Beginning for…